open access

Vol 18, No 2 (2011)
Review paper
Published online: 2011-03-10
Get Citation

Primary synovial sarcoma of the heart

Lei Zhang, Jianjun Qian, Zhongdong Li, Hua Jing
Cardiol J 2011;18(2):128-133.

open access

Vol 18, No 2 (2011)
Review articles
Published online: 2011-03-10

Abstract

Primary synovial sarcoma of the heart is very rare, accounting for 5% of cardiac malignancies. Of the few cases reported in the literature to date, nearly all have had a very poor outcome. We present a further case. This uncommon malignancy has no specific symptoms during its development, which results in delayed diagnosis. Echocardiography, chest computed tomography, and magnetic resonance imaging can provide effective information about this tumor. With the identification of the characteristic and diagnostic chromosomal abnormality t(X; 18), this malignancy will become increasingly recognized. Synovial sarcoma of the heart requires surgical intervention to improve the prognosis. Adjuvant and/or genetic therapy pre- or postoperation can help prolong life. Chemotherapy is usually recommended as it may benefit the patients. The key to treatment in the future is to find new therapeutic agents. Further elucidation of the effects of this chromosomal abnormality may lead to better-directed therapies in future. (Cardiol J 2011; 18, 2: 128-133)

Abstract

Primary synovial sarcoma of the heart is very rare, accounting for 5% of cardiac malignancies. Of the few cases reported in the literature to date, nearly all have had a very poor outcome. We present a further case. This uncommon malignancy has no specific symptoms during its development, which results in delayed diagnosis. Echocardiography, chest computed tomography, and magnetic resonance imaging can provide effective information about this tumor. With the identification of the characteristic and diagnostic chromosomal abnormality t(X; 18), this malignancy will become increasingly recognized. Synovial sarcoma of the heart requires surgical intervention to improve the prognosis. Adjuvant and/or genetic therapy pre- or postoperation can help prolong life. Chemotherapy is usually recommended as it may benefit the patients. The key to treatment in the future is to find new therapeutic agents. Further elucidation of the effects of this chromosomal abnormality may lead to better-directed therapies in future. (Cardiol J 2011; 18, 2: 128-133)
Get Citation

Keywords

heart; pathology; surgery; synovial sarcoma; tumor

About this article
Title

Primary synovial sarcoma of the heart

Journal

Cardiology Journal

Issue

Vol 18, No 2 (2011)

Article type

Review paper

Pages

128-133

Published online

2011-03-10

Bibliographic record

Cardiol J 2011;18(2):128-133.

Keywords

heart
pathology
surgery
synovial sarcoma
tumor

Authors

Lei Zhang
Jianjun Qian
Zhongdong Li
Hua Jing

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl